Science
AstraZeneca seeks FDA nod for HUTCHMED lung-cancer drug combo
ORPATHYS with TAGRISSO targets advanced disease that progressed after EGFR therapy.
Published: September 29, 2026 · 1 min read
HUTCHMED said Tuesday that AstraZeneca has filed with the U.S. Food and Drug Administration for approval of the ORPATHYS–TAGRISSO combination to treat patients with advanced lung cancer.
The companies said the combination extended progression-free survival and improved overall survival compared with chemotherapy in patients whose cancer progressed after prior EGFR-targeted treatment. EGFR, or epidermal growth factor receptor, is a protein on cell surfaces that helps cells grow and divide; mutations in the pathway drive a significant share of non-small-cell lung cancers, making later-line options after resistance a major clinical need.
ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. The therapy is already approved in China based on a separate Phase III study. The U.S. application puts the combination into a crowded late-stage oncology review queue as regulators weigh new choices for patients who have exhausted first-line targeted drugs and face limited alternatives beyond chemotherapy.
Newsletter
News. Context. What matters.
One essential briefing, written for people who would rather understand the story than scroll it.
Unsubscribe anytime. We don’t sell addresses.
Recommended
Science
From the space station, Joshua Kutryk describes the northern lights and relearning daily life as Canadian health studies get under way
In his first news conference from orbit, the Canadian Space Agency astronaut said he has lost five pounds and is taking part in Canadian-led research on astronaut health; a SpaceX cargo ship launched Tuesday with more experiments.
Science
About one in six Canadian doctors reports a disability at least some of the time, CMAJ census study finds
An Ottawa Hospital-led analysis of 2021 long-form census data found mental health and vision were the most commonly reported disabilities, and its authors call for more accessible medical workplaces.
Science
More than half of species assessed at risk since 2017 are overdue for federal listing decisions, SFU-led study finds
Only 17 of 288 COSEWIC-assessed species reached Cabinet on time; none of the marine mammals or marine fish assessed in the period had been forwarded by January 2025, researchers report in FACETS.